Vicore Pharma names 2027 board nomination committee
Shareholders may submit comments or proposals by January 15, 2027, ahead of the May 5, 2027 AGM.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vicore Pharma Holding AB announced the Nomination Committee for its 2027 Annual General Meeting. Three members were appointed by the three largest shareholders as of August 31, 2026: Staffan Lindstrand by HealthCap VII L.P., Jan Särlvik by the Fourth Swedish National Pension Fund, and Ivo Staijen by HBM Healthcare Investments (Cayman) Ltd. Vicore chairman Hans Schikan is also a member and convener.
The committee will prepare proposals on board size and elections, board and committee fees, the AGM chair, the auditor and auditor’s fees, and rules for appointing the committee for the 2028 AGM. The 2027 AGM is scheduled for May 5, 2027. Shareholders may submit comments or proposals by January 15, 2027; the committee’s proposals will be presented in the AGM notice and on the company website.
Key Figures
Key Terms
Nomination Committee technical
remuneration for committee work financial
convener technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
(Commission File No. 001-43312)
Vicore Pharma Holding AB
(Translation of registrant’s name into English)
Kornhamnstorg 53
SE-111 27 Stockholm,
Sweden
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐
Company Announcement
On November 3, 2026, Vicore Pharma Holding AB (the “Company”) issued a press release announcing the composition of the Company's nomination committee for the 2027 Annual General Meeting, which will take place on May 5, 2027. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.
The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Exhibits |
|
|
|
99.1 | Press Release, dated November 3, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vicore Pharma Holding AB |
|
|
|
|
| By: | /s/ Ahmed Mousa |
| Name: Title: | Ahmed Mousa Chief Executive Officer |
Date: November 3, 2026
Exhibit 99.1
Vicore Announces the Nomination Committee for the 2027 Annual General Meeting
Stockholm, Sweden & Cambridge, Mass., November 3, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM). The three largest shareholders as of August 31, 2026, have each appointed a member to the Committee.
The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särlvik, appointed by the Fourth Swedish National Pension Fund, and Ivo Staijen, appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore’s chairman, Hans Schikan, is also a member and acts as the convener of the Committee.
The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected at the AGM, the election of a chairman and other members of the board, board fees, remuneration for committee work, election of a chairman of the AGM, election of auditor, auditor’s fees, and proposals for rules for the appointment of the Nomination Committee for the 2028 AGM.
The AGM will take place on May 5, 2027. Shareholders who wish to submit their comments or proposals to the Nomination Committee may do so no later than January 15, 2027, by email to info@vicorepharma.com, or by letter to Vicore Pharma Holding AB, Kornhamnstorg 53, 111 27 Stockholm. The Nomination Committee’s proposals will be presented in the notice convening the AGM and on the company’s website.
For further information, please contact:
Hans Jeppsson, CFO, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Vicore Pharma Holding AB (publ) | Kornhamnstorg 53, SE-111 27 Stockholm, Sweden
Phone: +46 (0)31 78 80 560 | VAT nr SE556680380401 | www.vicorepharma.com